FDA 483 - Michael Lissy, M.D. - May 09, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Michael Lissy, M.D., a clinical investigator in Neu-Ulm, Bavaria, revealed a failure to prepare or maintain adequate case histories for a study protocol. Specifically, issues included the destruction of sealed code break emergency envelopes before verification and a lack of documentation regarding subject positioning for vital sign measurements as required by the protocol. These deficiencies indicate significant concerns with data integrity and adherence to study protocols.
ID · fe273ca0-6126-42e9-b465-20e22cb8a327